Insmed | INSM - Operating Profit

Stock Price
152.51
Daily Change
-4.65 -2.96%
Monthly
-12.95%
Yearly
87.26%
Q1 Forecast
152.04

Insmed reported $-261.35M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025